Clinical applications of TNF-alpha in cancer.
High-dose TNF-alpha plus chemotherapy, with or without IFN-gamma, can be safely administered regionally through isolated limb perfusion. This procedure produced between 70% and 80% complete remission in cases of in transit melanoma metastases and between 25% and 36% complete remission in cases of inextirpable soft-tissue sarcomas. Dual targeting is involved; TNF-alpha and IFN-gamma induce apoptosis of angiogenic endothelium, while melphalan induces apoptosis of tumour cells.
Lejeune
F J
FJ
Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier UniversitaireVaudois (CHUV), Rue du Bugnon 46, CH-1011, Lausanne, Switzerland. Ferdy.Lejeune@chuv.hospvd.ch
Rüegg
C
C
Liénard
D
D
D010478:Chemotherapy, Cancer, Regional Perfusion; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000502:physiology; D006801:Humans; D007371:Interferon-gamma / Q000502:physiology; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000098:blood supply / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D012509:Sarcoma / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma